| Literature DB >> 27434108 |
Amre Nasr1,2,3, Amir Abushouk1,2, Anhar Hamza4, Emmanuel Siddig5, Ahmed H Fahal5.
Abstract
Eumycetoma is a progressive and destructive chronic granulomatous subcutaneous inflammatory disease caused by certain fungi, the most common being Madurella mycetomatis. The host defence mechanisms against fungi usually range from an early non-specific immune response to activation and induction of specific adaptive immune responses by the production of Th-1 and Th-2 cytokines. The aim of this study is to determine the levels of Th-1 and Th-2 cytokines in patients infected with Madurella mycetomatis, and the association between their levels and disease prognosis. This is a descriptive cross-sectional study conducted at the Mycetoma Research Centre, University of Khartoum, Sudan, where 70 patients with confirmed M. mycetomatis eumycetoma were enrolled; 35 with, and 35 without surgical excision. 70 healthy individuals from mycetoma endemic areas were selected as controls. The levels of serum cytokines were determined by cytometric bead array technique. Significantly higher levels of the Th-1 cytokines (IFN-γ, TNF-α, IL-1β and IL-2) were recorded in patients treated with surgical excision, compared to those treated without surgical excision. In contrast, the Th-2 cytokines (IL-4, IL-5, IL-6 and IL-10) were significantly lower in patients treated with surgical excision compared to those treated without surgical excision. In conclusion, the results of this study suggest that cell-mediated immunity can have a role to play in the pathogenesis of eumycetoma.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27434108 PMCID: PMC4951069 DOI: 10.1371/journal.pntd.0004862
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Distribution of gender, medical treatment, size of lesions and presence of grains among the study population.
| Study groups | Controls | Mycetoma Patients | |||
|---|---|---|---|---|---|
| Without surgical excision | With surgical excision | ||||
| Female n = 49 (35%) | 35 (71.4%) | 8 (16.3%) | 6 (12.2%) | 0.55 (0.44 to 4.67) | |
| Male n = 91 (65%) | 35 (38.5%) | 27 (29.7%) | 29 (31.9%) | ||
| Itraconazole 200 mg bd n = 46 (66%) | NA | 11 (24%) | 35 (76%) | ||
| Ketoconazole 400 mg bd n = 24 (34%) | NA | 24 (100%) | 0 (0%) | ||
| No mass n = 1 (2%) | NA | 0 (0%) | 1 (100%) | ||
| Less than 5 cm n = 12 (17%) | NA | 7 (58.3%) | 5 (41.7%) | ||
| 5–10 cm n = 33 (47%) | NA | 20 (60.6%) | 13 (39.4%) | ||
| More than 10 cm n = 24 (34%) | NA | 8 (33.3%) | 16 (66.7%) | ||
| None n = 52 (74%) | NA | 25 (48.1%) | 27 (51.9%) | 0.28 (-0.15 to 0.27) | |
| Present n = 18 (26%) | NA | 10 (55.6%) | 8 (44.4%) | ||
‡ P values are derived from comparison between the study groups using one way ANOVA test.
₸ P values are derived from comparison within mycetoma patients, treated with surgical excision compared to those treated without surgical excision using Student’s t test.
* NA not applicable
Description of median and range of cytokines (IFN-γ, TNF-α, IL-1B, IL-2, IL-4, IL-5, IL-6, IL-10 and IL-13) level/μl in different study groups.
| Cytokines | Controls | Without Surgery | With Surgery | ||||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | P-value | |
| IFN-γ | 4.61 | 1.19 | 21.53 | 7.46 | 27.17 | 10.39 | <0.001 |
| TNF-α | 3.37 | 2.36 | 6.59 | 4.68 | 21.17 | 7.63 | <0.001 |
| IL-1 β | 3.44 | 20.93 | 2.58 | 0.9 | 2.22 | 0.14 | 0.913 |
| IL-2 | 0.19 | 0.22 | 9.65 | 2.54 | 17.21 | 5.17 | <0.001 |
| IL-4 | 1.01 | 0.35 | 4.99 | 0.77 | 2.42 | 1.53 | <0.001 |
| IL-5 | 0.6 | 1.11 | 3.12 | 1.35 | 1.04 | 0.16 | <0.001 |
| IL-6 | 0.98 | 0.41 | 30.61 | 4.49 | 20.52 | 9.63 | <0.001 |
| IL-10 | 3.7 | 1.48 | 21.69 | 2.37 | 16.36 | 6.9 | <0.001 |
| IL-13 | 2.46 | 1.02 | 9.73 | 0.36 | 18.37 | 6.32 | <0.001 |
*p values are derived from one way ANOVA test.
Linear regression analysis of circulating cytokines (IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10 and IL-13) level/μl in mycetoma patients treated with surgical excision compared to those treated without surgical excision.
| Variables | IFN-γ | TNF-α | IL-1β | IL-2 | IL-4 | IL-5 | IL-6 | IL-10 | IL-13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | P-value | B | P-value | B | P-value | B | P-value | B | P-value | B | P-value | B | P-value | B | P-value | B | P-value | |
| 5.64 | 0.011 | 14.58 | <0.001 | -0.36 | 0.022 | 7.55 | <0.001 | -2.57 | <0.001 | -2.08 | <0.001 | -10.09 | <0.001 | -5.33 | <0.001 | 8.64 | <0.001 | |
| 1.33 to 9.96 | 11.56 to 17.6 | -0.67 to -0.05 | 5.61 to 9.50 | -3.14 to -1.99 | -2.54 to -1.62 | -13.68 to -6.51 | -7.79 to -2.87 | 6.51 to 10.781 | ||||||||||
| 6.62 | 0.013 | 12.69 | <0.001 | -0.75 | <0.001 | 6.59 | <0.001 | -2.82 | <0.001 | -2.38 | <0.001 | -7.66 | 0.005 | -3.58 | 0.05 | 9.28 | <0.001 | |
| 1.42 to 11.81 | 9.06 to 16.32 | -1.13 to -0.37 | 3.91 to 9.28 | -3.65 to -1.99 | -3.04 to -1.72 | -12.88 to -2.44 | -7.16 to 0.01 | 6.14 to 12.41 | ||||||||||
| -4.1 | 0.077 | -1.2 | 0.46 | -0.52 | 0.003 | -1 | 0.385 | -0.77 | 0.71 | -0.55 | 0.061 | -0.57 | 0.805 | -0.67 | 0.671 | 0.65 | 0.641 | |
| -0.13 | 0.104 | -0.1 | 0.15 | 0.01 | 0.602 | 0.08 | 0.05 | 0.01 | 0.73 | -0.01 | 0.916 | 0.08 | 0.306 | -0.05 | 0.32 | 0.08 | 0.095 | |
| 2.94 | 0.282 | -1.44 | 0.45 | -0.68 | 0.001 | -1.51 | 0.285 | -0.43 | 0.33 | -0.53 | 0.13 | 4.32 | 0.118 | 2.46 | 0.195 | 0.71 | 0.672 | |
| 7.1 | <0.001 | 5.23 | <0.001 | -0.21 | 0.029 | 0.26 | 0.692 | -0.07 | 0.72 | -0.12 | 0.44 | 1.82 | 0.153 | -0.43 | 0.619 | -1.31 | 0.088 | |
| 3.55 | 0.086 | 2.27 | 0.12 | 0.13 | 0.378 | 2.96 | 0.006 | -0.29 | 0.36 | -0.01 | 0.98 | -0.92 | 0.651 | -2.31 | 0.104 | -0.25 | 0.842 | |
*B represents unstandardized coefficients
B (95%CI) adjusted with gender, medical treatments, size of lesions and presence of grains.